Trial · NCT05795062
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
NCT05795062, Completed, Pfizer; results first posted 2024-11-22
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Treatment Patterns Among Patients With Venous Thromboembolism in the United States. Trials, record NCT05795062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05795062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment Patterns Among Patients With Venous Thromboembolism in the United States
- NCT number
- NCT05795062
- Status
- Completed
- Enrollment
- 13,945 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Venous Thromboembolism
- Interventions
- apixaban, warfarin
- First posted
- 2023-04-03
- Last updated
- 2024-11-22
- Results first posted
- 2024-11-22
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | From hospital discharge date through 30 days following discharge date (from the data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Following discharge from inpatient hospitalization, participants who continued apixaban or warfarin, respectively, in the outpatient setting (with outpatient treatment claim occurring on or within 30-days following the hospital discharge date) were identified. |
| Primary | Mean Number of Persistent Days | From the index date until the first of treatment discontinuation, treatment switch, or the end of follow-up, whichever occurred first (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Persistent days was defined as the number of days from the index date until the first of the following: treatment discontinuation, treatment switch, or the end of follow-up. Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Discontinuation was defined as greater than or equal to (\>=) 30-day gap from the run-out of days supply of the treatment (post-discharge) index prescription (that is, apixaban or warfarin) to date of next claim for the respective therapy or with no other claims for the respective therapy. The date of discontinuation was last day of day's supply of the last filled prescription. Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Discontinuation was defined as \>= 30-day gap from the run-out of days supply of the treatment (post-discharge) index prescription (that is, apixaban or warfarin) to date of next claim for the respective therapy or with no other claims for the respective therapy. The date of discontinuation was last day of day's supply of the last filled prescription. Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Participants were considered to have switched if they filled a prescription for oral anticoagulant (OAC) other than apixaban or warfarin, respectively (identified through national drug codes \[NDC\] codes in longitudinal prescription claims \[LRx\]) or for parenteral anticoagulant (PAC) within 30 days before or after the run-out date of index treatment. The date of the switch was defined as date of the prescription of such a therapy (OAC or PAC). Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Percentage of Participants Who Switched From Index Treatment at Month 12 Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Participants were considered to have switched if they filled a prescription for OAC other than apixaban or warfarin, respectively (identified through NDC codes in LRx) or for PAC within 30 days before or after the run-out date of index treatment. The date of the switch was defined as date of the prescription of such a therapy (OAC or PAC). Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Median Time to Discontinuation From the Index Treatment | From initiation of index treatment post-discharge till its discontinuation (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Time from treatment index date to discontinuation date was described in this outcome measure. Discontinuation was defined as \>= 30-day gap from the run-out of days supply of the treatment (post-discharge) index prescription (that is, apixaban or warfarin) to date of next claim for the respective therapy or with no other claims for the respective therapy. The date of discontinuation was last day of day's supply of the last filled prescription. Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Primary | Median Time to Switch From the Index Treatment | From initiation of index treatment post-discharge till switch (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Time from treatment index date to treatment switch date was described in this outcome measure. Participants were considered to have switched if they filled a prescription for OAC other than apixaban or warfarin, respectively (identified through NDC codes in LRx) or for PAC within 30 days before or after the run-out date of index treatment. The date of the switch was defined as date of the prescription of such a therapy (OAC or PAC). Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Secondary | Incidence Rate of Recurrent VTE Events | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Recurrent VTE was defined as inpatient hospitalization with a primary diagnosis of VTE occurring 7 or more days after the first hospitalization discharge date. The date of the first observed event was flagged. Incidence rate was defined as the number of events (recurrent VTE) per 100 participant years. Treatment index date: date of first outpatient apixaban or warfarin claim. |
| Secondary | Median Time to Recurrent VTE | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Recurrent VTE was defined as inpatient hospitalization with a primary diagnosis of VTE occurring 7 or more days after the first hospitalization discharge date. The date of the first observed event was flagged. Treatment index date: date of first outpatient apixaban or warfarin claim. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | From hospital discharge date through 30 days following discharge date (from the data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Mean Number of Persistent Days | From the index date until the first of treatment discontinuation, treatment switch, or the end of follow-up, whichever occurred first (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Days | MEAN |
| PRIMARY | Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | At 6 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Percentage of Participants Who Switched From Index Treatment at Month 12 Post-Discharge Index Date | At 12 Months post-discharge index date (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Percentage of Participants | NUMBER |
| PRIMARY | Median Time to Discontinuation From the Index Treatment | From initiation of index treatment post-discharge till its discontinuation (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
| PRIMARY | Median Time to Switch From the Index Treatment | From initiation of index treatment post-discharge till switch (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
| SECONDARY | Incidence Rate of Recurrent VTE Events | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Events per 100 participant-years | NUMBER |
| SECONDARY | Median Time to Recurrent VTE | From first hospitalization discharge date to subsequent inpatient hospitalization for VTE (data retrieved for 5.5 years and retrospective data evaluated in approximately 7 months of this study) | Eligible participants whose data was extracted and evaluated in this study and was evaluable for analysis. | Months | MEDIAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | Apixaban | 11966 | Participants | ||
| Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | Warfarin | 1979 | Participants | ||
| Mean Number of Persistent Days | Apixaban | 233.5 | Standard Deviation 302.9 | Days | |
| Mean Number of Persistent Days | Warfarin | 242.6 | Standard Deviation 304.4 | Days | |
| Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | Apixaban | 50.5 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | Warfarin | 52.2 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | Apixaban | 72.9 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | Warfarin | 75.2 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | Apixaban | 6.0 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | Warfarin | 20.9 | Percentage of Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Apixaban | 11,966 | |
| Overall Study | STARTED | Warfarin | 1,979 | |
| Overall Study | COMPLETED | Apixaban | 11,966 | |
| Overall Study | COMPLETED | Warfarin | 1,979 | |
| Overall Study | NOT COMPLETED | Apixaban | 0 | |
| Overall Study | NOT COMPLETED | Warfarin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Apixaban | 0 | 0 |
| Total, all-cause mortality | Warfarin | 0 | 0 |
| Total, other adverse events | Apixaban | 0 | 0 |
| Total, other adverse events | Warfarin | 0 | 0 |
| Total, serious adverse events | Apixaban | 0 | 0 |
| Total, serious adverse events | Warfarin | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Apixaban vs Warfarin: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05795062
GET https://conductscience.org/api/trials/v1/NCT05795062/results?page=2